Bionano Genomics amends convertible debentures, reduces near-term payments, conversion price to $0.27

Bionano Genomics, Inc.

Amendment defers December 2024 redemption; monthly payments cut from $1M to $500k for Jan-Jul 2025, then rise to $1.375M from Aug 2025.
Conversion price reduced from $2.00 to $0.27; $15M principal convertible into 55.6M shares; 45.6M unregistered.
Company issued 5M shares as consideration; forbears from redemption notices until July 31, 2025.
Company to file registration statement for resale of shares by Jan 7, 2025.
Canaccord Genuity acted as exclusive financial advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.